➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Merck
Dow
Boehringer Ingelheim

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Litigation Details for Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Alcon Research, Ltd. v. Watson Laboratories, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-03-03 1 expiration of U.S. Patent Nos. 7,947,295 (“the ’295 patent”) and 8,921,337 (“the ’337 patent”). … (Infringement of U.S. Patent No. 7,947,295) 29. Alcon incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title…declaratory judgment of patent infringement under 28 U.S.C. §§ 2201 and 2202 and the patent laws of the United…’337 patents, and thus seeks FDA approval to engage in conduct that will infringe Alcon’s patent rights External link to document
2017-06-26 108 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,662,398 B2; . (Noreika, Maryellen… 28 September 2018 1:16-cv-00129 830 Patent None District Court, D. Delaware External link to document
2017-07-21 115 SERVICE of Alcon's Initial Claim Chart - U.S. Patent No. 9,662,398 filed by Alcon Research, Ltd..(Blumenfeld… 28 September 2018 1:16-cv-00129 830 Patent None District Court, D. Delaware External link to document
2017-08-25 125 SERVICE of Alcon's Final Claim Chart - U.S. Patent No. 9,662,398 filed by Alcon Research, Ltd..(Noreika, … 28 September 2018 1:16-cv-00129 830 Patent None District Court, D. Delaware External link to document
2017-09-15 128 CLAIM CONSTRUCTION OPENING BRIEF for U.S. Patent No. 9,662,398 filed by Alcon Research, Ltd.. (Attachments… 28 September 2018 1:16-cv-00129 830 Patent None District Court, D. Delaware External link to document
2017-10-11 137 of Claim Construction Briefing for U.S. Patent No. 9,662,398 by Alcon Research, Ltd.. (Attachments: #… 28 September 2018 1:16-cv-00129 830 Patent None District Court, D. Delaware External link to document
2017-11-08 147 constructions for disputed terms in U.S. Patent Nos. 7,947,295 and 8,'921,337; WHEREAS, on …#39;295 patent col. 3 11. 26-33. The Court is not persuaded that, in the context of the patent as a whole…(See D.I. 58 at 7-12) Watson contends that the patent contains a clear disavowal of claim scope, making…embodiments." (D.I. 58 at 11) (quoting '295 patent col. 3 11. 26-33) In particular, Watson relies …amounts to a clear and unmistakable disavowal. The patent goes on to 1 This term appears External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Mallinckrodt
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.